Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283266 | 0.92 | PDE4B (0.66) | PDE4BADORA1 | |
| SCHEMBL14115743 | 0.92 | PDE4B (0.75) | PDE4BJAK2JAK3ADORA1 | |
| SCHEMBL14007513 | 0.90 | PDE4B (0.65) | PDE4B | |
| SCHEMBL13324412 | 0.89 | PDE4B (0.63) | PDE4BJAK2JAK3ADORA1 | |
| SCHEMBL3286186 | 0.88 | PDE4B (0.79) | PDE4BADORA1 | |
| SCHEMBL4935529 | 0.87 | PDE4B (0.62) | PDE4BADORA1 | |
| SCHEMBL4934425 | 0.87 | PDE4B (0.62) | PDE4BADORA1 | |
| SCHEMBL14034599 | 0.87 | PDE4B (0.62) | PDE4BADORA1 | |
| SCHEMBL14115774 | 0.86 | PDE4B (0.77) | PDE4B | |
| SCHEMBL8279419 | 0.85 | PDE4B (0.61) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709497-B2 | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20070280971-A1 | Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | PDE4B, PDE3B, PDE4A | PDE4B 1/4885JAK2 707/4885JAK3 1235/4885 |
| US-20070280971-A1 | Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor | PDE4B, PDE4A, PDE3B | PDE4B 1/4885JAK2 888/4885JAK3 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.